Serum Levels of Interleukin-6 and Interleukin-10 as Biomarkers for Hepatocellular Carcinoma in Egyptian Patients
Date
2015
Journal Title
Journal ISSN
Volume Title
Type
Article
Publisher
Hindawi Publishing Corporation
Series Info
ISRN hepatology;
Scientific Journal Rankings
Abstract
Interleukin-10 (IL-10) and interleukin-6 (IL-6) have been reported to be related to hepatocellular carcinoma (HCC) prognosis. This study aimed to investigate the clinical usefulness of serum levels of IL-6 and IL-10 as biomarkers for HCC among high-risk patients.
Description
MSA Google Scholar
Keywords
University for Serum, Interleukin-6, Interleukin-10, Biomarkers, Hepatocellular, Carcinoma
Citation
[1] P. P. Michielsen, S. M. Francque, and J. L. van Dongen, “Viral hepatitis and hepatocellular carcinoma,” World Journal of Surgical Oncology, vol. 3, article 27, 2005. [2] G. Castello, S. Costantini, and S. Scala, “Targeting the inflammation in HCV-associated hepatocellular carcinoma: a role in the prevention and treatment,” Journal of Translational Medicine, vol. 8, article 109, 2010. [3] P. P. Michielsen, S. M. Francque, and J. L. van Dongen, “Viral hepatitis and hepatocellular carcinoma,” World Journal of Surgical Oncology, vol. 3, article 27, 2005. [4] A. Rahman El-Zayadi,H.Abaza, S. Shawky,M.K.Mohamed,O. E. Selim, and H. M. Badran, “Prevalence and epidemiological features of hepatocellular carcinoma in Egypt—a single center experience,” Hepatology Research, vol. 19, no. 2, pp. 170–179, 2001. [5] S. M. Attalla, S. M. El-Azab, A. A. El-Bakary et al., “Is aflatoxin B1 a common risk factor for hepatocellular carcinoma?” Mansoura Journal of Forensic Medicine and Clinical Toxicology, vol. 17, no. 2, pp. 15–24, 2009. [6] W. A. Anwar, H. M. Khaled, H. A. Amra, H. El-Nezami, and C. A. Loffredo, “Changing pattern of hepatocellular carcinoma (HCC) and its risk factors in Egypt: possibilities for prevention,” Mutation Research, vol. 659, no. 1-2, pp. 176–184, 2008. [7] N. I. Zakhary, M. M. El-Merzabani, N. M. El-Sawi, S. M. Saleh, M. M.Moneer, and R. H.Mohamad, “Impact of different biochemical markers in serum of patients with benign and malignant liver diseases,” Journal of Advanced Research, vol. 2, no. 1, pp. 49–55, 2011. [8] J. M. Llovet, A. Burroughs, and J. Bruix, “Hepatocellular carcinoma,” The Lancet, vol. 362, no. 9399, pp. 1907–1917, 2003. [9] J. A. Marrero, “Hepatocellular Carcinoma,” in Hepatology: A Textbook of Liver Disease, D. Zakim and T. D. Boyer, Eds., pp. 1005–1030, WB Saunders, Philadelphia, Pa, USA, 6th edition, 2012. [10] E.M. Lehman, A. S. Soliman, K. Ismail et al., “Patterns of hepatocellular carcinoma incidence in Egypt from a populationbased cancer registry,” Hepatology Research, vol. 38, no. 5, pp. 465–473, 2008. [11] D. Y. Kim, J.W. Kim, R. Kuromatsu, S. H. Ahn, T. Torimura, and M. Sherman, “Controversies in surveillance and early diagnosis of hepatocellular carcinoma,” Oncology, vol. 81, no. 1, pp. 56–60, 2011. [12] W. M. Korn, “Moving toward an understanding of the metastatic process in hepatocellular carcinoma,” World Journal of Gastroenterology, vol. 7, no. 6, pp. 777–778, 2001. [13] A.-R.N. Zekri, M. S. El-dinAshour,A.Hassan, H. M. A. El-Din, A. M. R. El-Shehaby, and M. A. Abu-Shady, “Cytokine profile in Egyptian hepatitis C virus genotype-4 in relation to liver disease progression,” World Journal of Gastroenterology, vol. 11, no. 42, pp. 6624–6630, 2005. [14] G.-Y. Chau, C.-W. Wu, W.-Y. Lui et al., “Serum interleukin-10 but not interleukin-6 is related to clinical outcome in patients with resectable hepatocellular carcinoma,” Annals of Surgery, vol. 231, no. 4, pp. 552–558, 2000. [15] A. Wieckowska, B. G. Papouchado, Z. Li, R. Lopez, N. N. Zein, and A. E. Feldstein, “Increased hepatic and circulating interleukin-6 levels in human nonalcoholic steatohepatitis,” American Journal of Gastroenterology, vol. 103, no. 6, pp. 1372– 1379, 2008. [16] W. E. Naugler and M. Karin, “The wolf in sheep’s clothing: the role of interleukin-6 in immunity, inflammation and cancer,” Trends in Molecular Medicine, vol. 14, no. 3, pp. 109–119, 2008. [17] C.-Y. Hsia, T.-I. Huo, S.-Y. Chiang et al., “Evaluation of interleukin-6, interleukin-10 and human hepatocyte growth factor as tumor markers for hepatocellular carcinoma,” European Journal of Surgical Oncology, vol. 33, no. 2, pp. 208–212, 2007. [18] A. Taylor, J. Verhagen, K. Blaser, M. Akdis, and C. A. Akdis, “Mechanisms of immune suppression by interleukin-10 and transforming growth factor-𝛽��: the role of T regulatory cells,” Immunology, vol. 117, no. 4, pp. 433–442, 2006. [19] G. Kuo, Q.-L. Choo, H. J. Alter et al., “An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis,” Science, vol. 244, no. 4902, pp. 362–364, 1989. [20] A.-R. N. Zekri, A. A. Bahnassy, S. M. Shaarawy et al., “Hepatitis C virus genotyping in relation to neu-oncoprotein overexpression and the development of hepatocellular carcinoma,” Journal of Medical Microbiology, vol. 49, no. 1, pp. 89–95, 2000. [21] A.Voller, A. Bartlett, andD. E. Bidwell, “Enzyme immunoassays with special reference to ELISA techniqies,” Journal of Clinical Pathology, vol. 31, no. 6, pp. 507–520, 1978. [22] L.-X. Qin and Z.-Y. Tang, “The prognostic molecular markers in hepatocellular carcinoma,”World Journal ofGastroenterology, vol. 8, no. 3, pp. 385–392, 2002. [23] H. T.Mollay and K. A. Evelyn, “Determination of bilirubin with photoelectric colorimeter,”The Journal of Biological Chemistry, vol. 119, pp. 481–485, 1937. [24] R. J. Henry, N. Chiamori, O. J. Gloub, and S. Berkman, “Revised spectrophotometric methods for the determination of glutamic-oxalacetic transaminase, glutamic-pyruvic transaminase, and lactic acid dehydrogenase,” American journal of clinical pathology, vol. 34, pp. 381–398, 1960. [25] A. E. Pinnell and B. E. Northam, “New automated dye binding method for serum albumin determination with bromcresol purple,” Clinical Chemistry, vol. 24, no. 1, pp. 80–86, 1978. [26] A. J. Quick, “Determination of prothrombin,” American Journal of Clinical Pathology, vol. 246, pp. 517–519, 1963. [27] W. Groner and E. Epstein, “Counting and sizing of blood cells using light scattering,” in Advances in HematologicalMethods, J. M. England and O. W. Van Assendelft, Eds., pp. 567–568, CRC Press, Boca Raton, Fla, USA, 1982. [28] S. Bolton and C. Bon, Pharmaceutical Statistics: Practical and Clinical Applicationsedition, Marcel Dekker, New York, NY, USA, 4th edition, 2003. [29] E. S. Bialecki and A.M. Di Bisceglie, “Diagnosis of hepatocellular carcinoma,” HPB, vol. 7, no. 1, pp. 26–34, 2005. [30] Q.Wang,W. Luan, G. A. Villanueva et al., “Clinical prognostic variables in young patients (under 40 years) with hepatitis B virus-associated hepatocellular carcinoma,” Journal of Digestive Diseases, vol. 13, no. 4, pp. 214–218, 2012. [31] A. Budhu andW.W. Xin, “The role of cytokines in hepatocellular carcinoma,” Journal of Leukocyte Biology, vol. 80, no. 6, pp. 1197–1213, 2006. [32] C. Porta, M. De Amici, S. Quaglini et al., “Circulating interleukin-6 as a tumor marker for hepatocellular carcinoma,” Annals of Oncology, vol. 19, no. 2, pp. 353–358, 2008. [33] L. Zhou, J.-A. Rui, S.-B. Wang, S.-G. Chen, and Q. Qu, “The significance of serum AFP cut-off values, 20 and 400ng/mL in curatively resected patients with hepatocellular carcinoma and cirrhosis might be of difference,” Hepato-Gastroenterology, vol. 59, no. 115, pp. 840–843, 2012. [34] S. B. Paul, M. S. Gulati, V. Sreenivas et al., “Evaluating patients with cirrhosis for hepatocellular carcinoma: value of clinical symptomatology, imaging and alpha-fetoprotein,” Oncology, vol. 72, no. 1, pp. 117–123, 2007. [35] M. Ishii,H.Gama,N.Chida et al., “Simultaneous measurements of serum 𝛼��-fetoprotein and protein induced by vitamin K absence for detecting hepatocellular carcinoma,” American Journal of Gastroenterology, vol. 95, no. 4, pp. 1036–1040, 2000. [36] H. Abdel-Haleem, S. El Kateb, N. Gohar, and E. Hamdy, “Evaluation of the diagnostic and prognostic value of AFP, PIVKA-II, VEGF and TGF-𝛽��1 in the diagnosis and follow up of patients with hepatocellular carcinoma,” Arab Journal Gastroenterology, vol. 8, no. 3, pp. 84–89, 2007. [37] M. E. El-Houseini, M. S. Mohammed, W. M. Elshemey, T. D. Hussein,O. S.Desouky, andA.A. Elsayed, “Enhanced detection of hepatocellular carcinoma,” Cancer Control, vol. 12, no. 4, pp. 248–253, 2005. [38] M. Abdel-Wahab, M. Mostafa, M. Sabry, M. El-Farrash, and T. Yousef, “Aflatoxins as a risk factor for hepatocellular carcinoma in Egypt, Mansoura Gastroenterology Center Study,” Hepato- Gastroenterology, vol. 55, no. 86-87, pp. 1754–1759, 2008. [39] L.Zhou, J. Liu, and F. Luo, “Serumtumor markers for detection of hepatocellular carcinoma,”World Journal ofGastroenterology, vol. 12, no. 8, pp. 1175–1181, 2006. [40] E. N. Debruyne and J. R. Delanghe, “Diagnosing and monitoring hepatocellular carcinoma with alpha-fetoprotein: new aspects and applications,” Clinica Chimica Acta, vol. 395, no. 1-2, pp. 19–26, 2008. [41] M.Martin and Z.Herceg, “Fromhepatitis to hepatocellular carcinoma: a proposedmodel for cross-talk between inflammation and epigenetic mechanisms,” Genome Medicine, vol. 4, no. 1, article 8, 2012. [42] M. Malaguarnera, I. Di Fazio, A. Laurino, M. A. Romeo, I. Giugno, and B. A. Trovato, “Role of the interleukin 6 in hepatocellular carcinoma,” Bulletin du Cancer, vol. 83, no. 5, pp. 379–384, 1996. [43] S.Maurizio, G. Lydia, D. Fabio et al., “Interleukin-6 and its soluble receptor in patients with liver cirrhosis and hepatocellular carcinoma,” World Journal of Gastroenterology, vol. 12, no. 16, pp. 2563–2568, 2006. [44] H. Ataseven, I. H. Bahcecioglu, N. Kuzu et al., “The levels of ghrelin, leptin, TNF-𝛼��, and IL-6 in liver cirrhosis and hepatocellular carcinoma due to HBV and HDV infection,” Mediators of Inflammation, vol. 2006, no. 4, Article ID 78380, 2006. [45] M. G. Tovey, J. Gugenheim, J. Guymarho et al., “Genes for interleukin-1, interleukin-6, and tumor necrosis factor are expressed at markedly reduced levels in the livers of patients with severe liver disease,” Autoimmunity, vol. 10, no. 4, pp. 297– 310, 1991. [46] H. A. Metwaly, M. M. H. Al-Gayyar, S. Eletreby, M. A. Ebrahim, and M. M. El-Shishtawy, “Relevance of serum levels of interleukin-6 and syndecan-1 in patients with hepatocellular carcinoma,” Scientia Pharmaceutica, vol. 80, no. 1, pp. 179–188, 2012. [47] X. Jin, T. A. Zimmers, E. A. Perez, R. H. Pierce, Z. Zhang, and L. G. Koniaris, “Paradoxical effects of short- and long-term interleukin-6 exposure on liver injury and repair,” Hepatology, vol. 43, no. 3, pp. 474–484, 2006. [48] V. W.-S. Wong, J. Yu, A. S.-L. Cheng et al., “High serum interleukin-6 level predicts future hepatocellular carcinoma development in patients with chronic hepatitis B,” International Journal of Cancer, vol. 124, no. 12, pp. 2766–2770, 2009. [49] M. Zhu and G. V. Paddock, “Expression of the hepatocyte growth factor-like protein gene in human hepatocellular carcinoma and interleukin-6-induced increased expression in hepatoma cells,” Biochimica et Biophysica Acta, vol. 1449, no. 1, pp. 63–72, 1999. [50] C. Zou, H. Zhang, Q. Li et al., “Heme oxygenase-1: a molecular brake on hepatocellular carcinoma cell migration,” Carcinogenesis, vol. 32, no. 12,Article ID bgr225, pp. 1840–1848, 2011. [51] Y. Liu, P. K. Li, C. Li, and J. Lin, “Inhibition of STAT3 signaling blocks the anti-apoptotic activity of IL-6 in human liver cancer cells,” The Journal of Biological Chemistry, vol. 285, no. 35, pp. 27429–27439, 2010. [52] K. Kovalovich,W. Li, R. DeAngelis, L. E. Greenbaum, G. Ciliberto, and R. Taub, “Interleukin-6 protects against Fas-mediated death by establishing a critical level of anti-apoptotic hepatic proteins FLIP, Bcl-2, and Bcl-xL,” The Journal of Biological Chemistry, vol. 276, no. 28, pp. 26605–26613, 2001. [53] V. Wallenius, K. Wallenius, M. Hisaoka et al., “Retarded liver growth in interleukin-6-deficient and tumor necrosis factor receptor-1-deficient mice,” Endocrinology, vol. 142, no. 7, pp. 2953–2960, 2001. [54] E. Hattori, K. Okumoto, T. Adachi et al., “Possible contribution of circulating interleukin-10 (IL-10) to anti-tumor immunity and prognosis in patients with unresectable hepatocellular carcinoma,” Hepatology Research, vol. 27, no. 4, pp. 308–313, 2003. [55] O. Delpuech, D. Buffello-Le Guillou, E. Rubinstein, C. F´eray, and M.-A. Petit, “The hepatitis C virus (HCV) induces a longterm increase of interleukin-10 production by human CD4+ T cells (H9),” European Cytokine Network, vol. 12, no. 1, pp. 69–77, 2001. [56] S. Beckebaum, X. Zhang, X. Chen et al., “Increased levels of interleukin-10 in serum from patients with hepatocellular carcinoma correlate with profound numerical deficiencies and immature phenotype of circulating dendritic cell subsets,” Clinical Cancer Research, vol. 10, no. 21, pp. 7260–7269, 2004. [57] G. A. Gastl, J. S. Abrams, D. M. Nanus et al., “Interleukin-10 production by human carcinoma cell lines and its relationship to interleukin-6 expression,” International Journal of Cancer, vol. 55, no. 1, pp. 96–101, 1993.